Association between visual acuity and medical and non-medical costs in patients with wet age-related macular degeneration in France, Germany and Italy

Drugs and Aging

Volumn 25, Issue 3, 2008, Pages 255-268

  Bandello, Francesco ^a   Augustin, Albert ^b   Sahel, José Alain ^c   Benhaddi, Hicham ^d   Negrini, Cristina ^e   Hieke, Klaus ^f   Berdeaux, Gilles H ^g,h,i   Chaine, Gilles ^j   Weber, Michel ^k   Quentel, Gabriel ^l   Cohen, Salomon Yves ^l   Mauget Faysse, Martine ^m   Brasseur, Gérard ⁿ   Korobelnik, Jean François ^o   Benchaboune, Mustapha ^p   Charlin, Jean François ^q   Augustin, ^r   Weinhold, ^m   Kaut, ^m   Hyppa, ^m   Jurgeit, ^m   Incorvaia, Carlo ^s   Menchini, Ugo ^t   Capobianco, ^t   Boscia, Francesco ^u   Malerba, ^v   Setaccioli, ^w   Varano, Monica ^x   Schiano, ^x   more..

^a UNIVERSITY OF UDINE   (Italy)

^b Augenklinik   (Germany)

^c CENTRE HOSPITALIER NATIONAL D OPHTALMOLOGIE DES QUINZE VINGTS   (France)

^d Aremis Consultants   (France)

^e Pbe Consulting   (Italy)

^f NEOS Health   (Switzerland)

^g Bioinformatique et Chimie Moléculaire   (France)

^h Alcon France   (France)

ⁱ Alcon France   (France)

^j AVICENNE HOSPITAL   (France)

^k HÔTEL DIEU   (France)

^l D'Imagerie et de Laser   (France)

^m Hôpital Charles Nicole ^*

ⁿ HÔPITAL CHARLES NICOLLE   (France)

^o HÔPITAL PELLEGRIN   (France)

^p SERVICE DE NEUROLOGIE   (France)

^q RENNES UNIVERSITY HOSPITAL   (France)

^r Hospital of Karlsruhe   (Germany)

^s UNIVERSITY HOSPITAL OF FERRARA   (Italy)

^t UNIVERSITY OF FLORENCE   (Italy)

^u POLICLINICO   (Italy)

^v UNIVERSITY OF CATANIA   (Italy)

^w SAN RAFFAELE HOSPITAL   (Italy)

^x IRCCS FONDAZIONE BIETTI   (Italy)

more..

Author keywords

[No Author keywords available]

Indexed keywords

TRIAMCINOLONE;

AGED; ARTICLE; CLINICAL TRIAL; DISEASE SEVERITY; ECONOMIC ASPECT; FEMALE; FRANCE; GERMANY; HEALTH CARE COST; HEALTH CARE DELIVERY; HUMAN; ITALY; LASER COAGULATION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OUTCOME ASSESSMENT; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; RETINA MACULA AGE RELATED DEGENERATION; VISUAL ACUITY;

EID: 40749140343     PISSN: 1170229X     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002512-200825030-00007     Document Type: Article

References (55)

1. Fine SL, Berger JW, Maguire MG, et al. Age-related macular degeneration. N Engl J Med 2000; 342 (7): 483-92
2. Bonastre J, Le Pen C, Anderson P, et al. The epidemiology, economics and quality of life burden of age-related macular degeneration in France, Germany, Italy and the United Kingdom. Eur J Health Econ 2002; 3 (2): 94-102
3. Gohdes DM, Balamurugan A, Larsen BA, et al. Age-related eye diseases: an emerging challenge for public health professionals. Prev Chronic Dis 2005 Jul; 2 (3): A17
4. Bressler NM. Age-related macular degeneration is the leading cause of blindness. JAMA 2004 Apr 21; 291 (15): 1900-1
5. Foran S, Wang JJ, Mitchell P. Causes of visual impairment in two older population cross-sections: the Blue Mountains Eye Study. Ophthalmic Epidemiol 2003 Oct; 10 (4): 215-25
6. Trautner C, Haastert B, Richter B, et al. Incidence of blindness in southern Germany due to glaucoma and degenerative conditions. Invest Ophthalmol Vis Sci 2003 Mar; 44 (3): 1031-4
7. Buch H, Nielsen NV, Vinding T, et al. 14-year incidence, progression, and visual morbidity of age-related maculopathy: the Copenhagen City Eye Study. Ophthalmology 2005 May; 112 (5): 787-98
8. Ferris III FL, Fine SL, Hyman L. Age-related macular degeneration and blindness due to neovascular maculopathy. Arch Ophthalmol 1984; 102 (11): 1640-2
9. Soubrane G, Haddad WM, Coscas G. Age-related macular degeneration. Presse Med 2002; 31 (27): 1282-7
10. Leibowitz HM, Krueger DE, Maunder LR, et al. The Framingham Eye Study monograph: an ophthalmological and epidemiological study of cataract, glaucoma, diabetic retinopathy, macular degeneration, and visual acuity in a general population of 2631 adults, 1973-1975. Surv Ophthalmol 1980; 24 Suppl.: 335-610
11. Korobelnik JF, Moore N, Blin P, et al. Estimating the yearly number of eyes with treatable neovascular age-related macular degeneration using a direct standardization method and a Markov model. Invest Ophthalmol Vis Sci 2006; 47 (10): 4270-6
12. Smith W, Assink J, Klein R, et al. Risk factors for age related macular degeneration: pooled findings from three continents. Ophthalmology 2001; 108 (4): 697-704
13. Delcourt C, Carriere I, Ponton-Sanchez A, et al. Light exposure and the risk of age-related macular degeneration: the Pathologies Oculaires Liees a l'Age (POLA) study. Arch Ophthalmol 2001 Oct; 119 (10): 1463-8
14. Transparency Commission. Verteporfin (Visudyne 15mg). 2003 Dec 17 [online]. Available from URL: http://www.hassante.fr/portail/upload/docs/ application/pdf/ct031800.pdf [Accessed 2008 Jan 31]
15. Pagliarini S, Moramarco A, Wormald RP, et al. Age-related macular disease in rural southern Italy. Arch Ophthalmol 1997 May; 115 (5): 616-22
16. Klaver CC, Assink JJ, van Leeuwen R, et al. Incidence and progression rates of age related maculopathy: the Rotterdam Study. Invest Ophthalmol Vis Sci 2001; 42 (10): 2237-41
17. Nuijten MJC, Berto P, Berdeaux G, et al. Trends in decision making process for pharmaceuticals in western European countries: a focus on emerging hurdles for obtaining reimbursement and a price. Eur J Health Econ 2001; 2: 162-9
18. National Institute for Health and Clinical Excellence [online]. Available from URL: http://www.nice.org.uk/ [Accessed 2008 Jan 9]
19. Smith DH, Fenn P, Drummond M. Cost effectiveness of photodynamic therapy with verteporfin for age related macular degeneration: the UK case. Br J Ophthalmol 2004; 88: 107-12
20. Greiner RA. Cost of care for patients with age-related macular degeneration in Switzerland and cost-effectiveness of treatment with verteporfin therapy. Semin Ophthalmol 2001; 6: 218-22
21. Sharma S, Bakal J, Sharma SM, et al. Drug pricing for a novel treatment for wet macular degeneration: using incremental cost-effectiveness ratios to ensure societal value. Can J Ophthalmol 2005; 40: 369-77
22. O'Neill C, Jamison J, McCulloch D, et al. Age-related macular degeneration: cost-of-illness issues. Drugs Aging 2001; 18: 233-41
23. Meads C, Hyde C. What is the cost of blindness. Br J Ophthalmol 2003; 87: 1201-4
24. Lafuma A, Brézin A, Lopatriello S, et al. Evaluation of non-medical costs associated with visual impairment in four European countries (France, Italy, Germany and the United Kingdom). Pharmacoeconomics 2006; 24 (2): 193-205
25. Lafuma A, Brezin A, Fagnani F, et al. Non-medical socioeconomic consequences attributable to visual impairment in France: a nation-wide approach. Eur J Health Econ 2006; 7 (3): 158-64
26. Bonastre J, Le-Pen C, Soubrane G, et al. The burden of age-related macular degeneration: results of a cohort study in two French referral centres. Pharmacoeconomics 2003; 21: 181-90
27. Garattini L, Castelnuovo E, Lanzetta P, et al. Direct medical costs of age-related macular degeneration in Italian hospital ophthalmology departments: a multicenter, prospective 1-year study. Eur J Health Econ 2004; 5: 22-7
28. Association des Epidemiologistes de Langue Francaise. Déontologie et bonnes pratiques en epidémiologie, recommandations de l'association des épidémiologistes de langue française. Paris: ADELF, 1997
29. CNIL [online]. Available from URL: http://www.CNIL.fr [Accessed 2008 Jan 9]
30. Sahel JA, Bandello F, Augustin A, et al. Health-related quality of life and utility in patients with age-related macular degeneration. Arch Ophthalmol 2007; 125 (7): 945-51
31. Augustin A, Sahel JA, Bandello F, et al. Anxiety and depression prevalence rates in age-related macular degeneration. Invest Ophthalmol Vis Sci 2007 Apr; 48 (4): 1498-503
32. Vidal (Cederom version 2004). Edition du Vidal. Paris: Vidal, 2004
33. Echelle nationale des coûts par GHM (en Euros): données 2003-2004 [online]. Available from URL: http://www.atih.sante.fr/ [Accessed 2008 Jan 31]
34. Nomenclature Générale des Actes Professionnels. Paris: UCANSS, 2003
35. Gelbe Liste Pharmindex [online]. Available from URL: http:// www.gelbe-liste.de [Accessed 2008 Jan 10]
36. Artzguppen - EBM - Einheitlicher Bewertungs maßstab [online]. Available from URL: http://www.kbv.de [Accessed 2008 Jan 31]
37. Prontuario Farmaceutico Nazionale. Decreto 20-12-2002. GU no. 4, 2003 Jan 7
38. Ministero della Sanità. Nomenclatore tarifffario delle prestazioni ambulatoriali DM 22.7.96. Gazzetta Ufficiale no. 216, 1996 Sep 14
39. Ministero della Sanità. Aggiornamento delle tarifffe delle prestazioni di assistenza ospedaliera di cui al DM 14.12.1994; DM 30.6.97. Supplemento Ordinario Gazzetta Ufficiale no. 209, 1997 Sep 8
40. Berdeaux G, Nordmann JP, Colin E, et al. Vision-related quality of life in patients suffering from age-related macular degeneration. Am J Ophthalmol 2005; 139: 271-9
41. Bandello F, Lafuma A, Berdeaux G. Public health impact of neovascular age-related macular degeneration treatments extrapolated from visual acuity. Invest Ophthalmol Vision Sci 2007 Jan; 48 (1): 96-103
42. DeBlack SS. Cigarette smoking as a risk factor for cataract and age-related macular degeneration: a review of the literature. Optometry 2003 Feb; 74 (2): 99-110
43. Klein R, Deng Y, Klein BE, et al. Cardiovascular disease, its risk factors and treatment, and age-related macular degeneration: Women's Health Initiative Sight Exam ancillary study. Am J Ophthalmol 2007 Mar; 143 (3): 473-83
44. Tan JS, Mitchell P, Smith W, et al. Cardiovascular risk factors and the long-term incidence of age-related macular degeneration: the Blue Mountains Eye Study. Ophthalmology 2007 Jun; 114 (6): 1143-50
45. Clemons TE, Milton RC, Klein R, et al. Age-Related Eye Disease Study Research Group: risk factors for the incidence of advanced age-related macular degeneration in the Age-Related Eye Disease Study (AREDS). AREDS report no. 19. Ophthalmology 2005 Apr; 112 (4): 533-9
46. Francis PJ, George S, Schultz DW, et al. The LOC387715 gene, smoking, body mass index, environmental associations with advanced age-related macular degeneration. Hum Hered 2007; 63 (3-4): 212-8
47. Souetre E, Thwaites RM, Yeardley HL. Economic impact of Alzheimer's disease in the United Kingdom: cost of care and disease severity for non-institutionalised patients with Alzheimer's disease. Br J Psychiatry 1999; 174: 51-5
48. Gragoudas ES, Adamis AP, Cunningham ET, et al. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med 2004; 351: 2805-16
49. D'Amico DJ, Goldberg MF, Hudson H, et al. Anecortave acetate as monotherapy for treatment of subfoveal neovascularization in age-related macular degeneration: twelve-month clinical outcomes. Ophthalmology 2003; 110: 2372-83
50. Auquier P, Auray JP, Berdeaux G, et al. French guidelines for the economic evaluation of health care technologies: methodological recommendations. Work carried out by the Members of the Collège des Économistes de la Santé (the French Health Economists Association) under the coordination of Émile Lévy and Gérard de Pouvourville. CES, Collège des économistes de la Santé: Paris, 2004 Sep: 1-86
51. Garattini L, Grilli R, Scopelliti D, et al. A proposal for Italian guidelines in pharmacoeconomics. Pharmacoeconomics 1995; 7: 1-6
52. German recommendations on health economic evaluation studies: revised version of the Hannover Consensus, 1995. Med Klin 2000; 95: 52-5
53. Brézin A, Lafuma A, Fagnani F, et al. Prevalence and burden of self-reported blindness and low vision for subjects living in institutions: a nation-wide survey. Health Qual Life Outcomes 2005; 3: 27
54. Brézin A, Lafuma A, Fagnani F, et al. Prevalence and burden of self-reported blindness, low vision and visual impairment in the French community: a nation-wide survey. Arch Ophthalmol 2005; 123: 1117-24
55. Centre for Eye Research Australia. The impact of age-related macular degeneration: a dynamic economic model and report by Access Economics Pty Limited, Victoria, Australia [online]. Available from URL: http://cera.unimelb. edu.au/publications/reports/access/access_amd.pdf [Accessed 2007 Jun 7]